Fund moves
71KShares reported
From a 13F filed Nov 16, 2026 covering holdings at Sep 30, 2026 — a quarter-end snapshot, not a live trade.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
CRL · NYSE · Life Sciences Tools & Services
Charles River Laboratories (CRL) · oqro.io/stocks/CRL · printed today. Every figure comes from a public filing, linked on the page online. Not investment advice.
Baskets of the companies that insiders, members of Congress or funds recently reported buying, each held under a written rule.
No open-market purchase by an insider of Charles River Laboratories was filed in the last 90 days. The latest on record was on Mar 4, 2026.
Since 2006, Charles River Laboratories insiders reported 16 open-market purchases and 7,135 sales on Forms 4 and 5, with purchases in 8 different years, most recently 2026.
In the last 90 days, 3 insiders of Charles River Laboratories (CRL) reported 6 open-market sales worth $20.3M in total on SEC Form 4. The largest seller by value was James C Foster, with $18.5M. Many insider sales follow a plan set in advance or cover taxes on stock awards; the filing says what was sold, not the reason.
No trade in Charles River Laboratories (CRL) was disclosed by a member of Congress in the last 12 months.
Charles River Laboratories's next results are expected on Feb 16, 2027, after the market closes. The date can move until the company confirms it. Insiders often trade in the weeks right after results.
From official filings only: SEC Forms 4, 5 and 144 for insiders, House and Senate periodic transaction reports for Congress, SEC Form 13F for funds, Form 8-K for company events and USAspending for federal contracts. Every record on OQRO links to its source. It is public data, not investment advice.
$333.25+1.09 (+0.33%)
Close of Nov 18, 2026, vs Nov 17 · end-of-day, not a live quote
+105.0% (+$170.72) from Nov 18, 2025 to Nov 18, 2026 · adjusted daily closes
Adjusted close went from $162.53 on Nov 18, 2025 to $333.25 on Nov 18, 2026 (+105.0%). Disclosed in this range: 12 insider trades, 10 pre-arranged insider sales, 0 Congress trades, and 36 13F position changes for 4 quarters ending in it.
Counts of filings OQRO holds, by the date each was filed or the award started. Every figure links to its official SEC, House, Senate or USAspending record.
Life Sciences Tools & Services company based in Wilmington, Massachusetts.
Last 12 months
+105.0%
Market value
$16B
S&P 500 +10.6% over the same dates. Prices adjusted for splits and dividends.
Short interest: 2.99M shares sold short (6.2% of shares outstanding), +5.4% vs the previous count, 2.2 days of normal trading to buy them back. FINRA, as of Oct 30, 2026.
Revenue
$983M
−2.2% vs the same quarter a year earlier
Free cash flow, last 12 months
$400M
This quarter $207M, a year earlier $178M
Net debt
$2.25B
Debt $2.45B, cash $200M, at Sep 26, 2026
Backlog
$675M
Work contracted but not yet delivered, as the company reports it
From the company's own quarterly and annual reports to the SEC. Free cash flow (cash from operations minus capital spending), net debt (debt minus cash) and 12-month totals are calculated by OQRO. Production rates, deliveries, approvals and guidance are in its results announcement of Nov 4, 2026.
Revenue, fiscal 2025
$4.02B
−0.9% vs the year before
Net income, fiscal 2025
−$144M
A loss for the year
Shares outstanding
47.9M
As of Oct 24, 2026
In fiscal 2025 the company spent $361M buying back its own shares. Cash actually paid, from its cash-flow statement.
New federal contracts from the last 12 months add up to 0.54% of that revenue. Contract money is usually earned over several years, so this is a size comparison, not a share of sales.
Fund moves
From a 13F filed Nov 16, 2026 covering holdings at Sep 30, 2026 — a quarter-end snapshot, not a live trade.
Fund moves
A Schedule 13G is filed by holders above 5% who say they will not try to influence the company. Index funds and large asset managers file most of them.
Shannon M Parisotto (CEVP, Disc & Safety Assessment) sold ~$743K of Charles River Laboratories
Planned salePrices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.
Written by software from the filings listed below · Oct 26, 2026
3 more points, with the facts they come from, are in OQRO Pro.
Sign up freeFMR LLC
Schedule 13G: passive · filed Nov 5, 2026 · 5.92M shares
Vanguard Capital Management
Schedule 13G: passive · filed Apr 29, 2026 · 3.63M shares
T. Rowe Price Associates, Inc.
Schedule 13G: passive · filed Nov 16, 2026 · 3.01M shares
Anyone owning more than 5% must file within days. Structured filings have existed since December 2024, so older stakes that were never amended may be missing.
Top officer leaving
“In addition to overseeing its Finance department as CFO, as Integra’s COO, Mr.”
8-K on sec.govTop officer leaving
“Foster, our current Chairman of the Board, President and Chief Executive Officer, intends to step down as Chief Executive Officer and Chairman of the Board, and Ms.”
8-K on sec.govTop officer leaving
“(the “Company”) of her intention to resign from her position as the Company’s Corporate Executive Vice President, Chief Financial Officer effective on September 29, 2025.”
1 insider sold ~$252K in the 60 days before
8-K on sec.govFrom the company's 8-K, 10-K and 10-Q filings over the last two years. A flag is a reason to read the filing, not a verdict: many departures are planned retirements and many listing notices are resolved. Insider sales are shown for timing only; they are separate filings.
Against the S&P 500 over the year
Since Nov 14, 2025, CRL is up 97.9% and the index fund is up 9.0%: 89 points ahead of the market. Traders call a stock that beats the index over a period a relative-strength leader.
How much CRL moves
End-of-day prices. These figures describe the past year and say nothing about what comes next.
Insiders of Charles River Laboratories reported 16 open-market purchases and 7,135 sales since 2006; purchases in 8 different years, most recently 2026.
| Year | Bought | Sold |
|---|---|---|
| 2026 | $4.4K1×1 trade | $52.1M21×21 trades |
| 2025 | $1.25M2×2 trades | $1.08M13×13 trades |
| 2024 | — | $14.4M25×25 trades |
| 2023 | $1.83M4×4 trades | $12.2M33×33 trades |
| 2022 | $328K1×1 trade | $25.5M74×74 trades |
| 2021 | — | $71M125×125 trades |
| 2020 | $1.68M2×2 trades | $50.8M66×66 trades |
| 2019 | — | $31.8M982×982 trades |
| 2018 | — | $36M1042×1,042 trades |
| 2017 | — | $30.8M637×637 trades |
| 2016 | — | $23.7M600×600 trades |
| 2015 | — | $30.8M657×657 trades |
| 2014 | — | $46.1M831×831 trades |
| 2013 | — | $61.7M695×695 trades |
| 2012 | — | $10.7M273×273 trades |
| 2011 | — | $10.7M182×182 trades |
| 2010 | $1801×1 trade | $44K3×3 trades |
| 2009 | $15K4×4 trades | $1.06M18×18 trades |
| 2008 | — | $13.8M388×388 trades |
| 2007 | — | $27M440×440 trades |
| 2006 | $4.1K1×1 trade | $2.92M30×30 trades |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
19 certified in FY2026 Q3, vs 15 a year earlier. 19 positions in total, median offered wage $106K a year.
Labor condition applications for H-1B workers certified by the Department of Labor, counted by decision date (FY2026 Q3: Apr 1, 2026 to Jun 30, 2026, the latest quarter published). A certified application is a step before a visa petition, not a hire or a visa, and one application can cover several positions. Matched by employer ID number or name.
Last results
Nov 4, 2026
Within the 30 days after it, until Dec 4, 2026
Next results, expected
Feb 16, 2027
after the market closes; the date can move until the company confirms it
Purchases after results
100%
10 of 10 insider purchases since 2016 came within 30 days after a results announcement
From Charles River Laboratories's own results filings (8-K Item 2.02) and its insiders' Forms 4 and 5. Many companies only let insiders trade in a period after results; OQRO does not know Charles River Laboratories's policy and only shows the pattern in the filings. A purchase made long after results, at a company whose insiders usually buy right after them, is marked “Bought outside the usual window”.
Short sale volume: 51.3% of the volume reported to FINRA over the last 20 trading days was marked short, below its 1-year average of 59.1%. FINRA daily files, to Nov 18, 2026.
Fails to deliver: 5,770 shares (about $1.96M) were not delivered on time for settlement on Oct 23, 2026. SEC fails-to-deliver data.
Short sale volume is not short interest. It counts trades marked short, including market makers selling short to fill buy orders, so it is a share of daily trading, not a count of bets against the stock. Fails to deliver have many causes, including processing delays, and are often resolved within days.